Please login to the form below

Not currently logged in
Email:
Password:

Merck enters Alzheimer's partnership

Merck has entered into a $289m research partnership with Alectos Therapeutics

Merck has entered into a research partnership with Alectos Therapeutics focused on compounds that modulate the enzyme -linked N-acetylglucosaminidase (O-GlcNAcase).

The deal, which is valued at $289m, gives Merck exclusive global rights to research, develop and commercialise compounds that modulate the target in return for an upfront payment, milestones, royalties, and research funding for Alectos' existing portfolio of compounds targeting Alzheimer's disease. 

The agreement calls for Alectos and Merck to partner on discovery and preclinical development, with Merck taking over full responsibility for clinical development. The companies may also develop products that modulate the enzyme as treatments for other neurological diseases.

Alectos was founded by researchers from Canada's Simon Frasier University.

11th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics